抗血小板生成素及其受体抗体在系统性红斑狼疮并发血小板减少发病机制中的作用

摘要

Thrombocytopenia is a common clinical manifestation of systemic lupus erythematosus (SLE) and is an independent risk factor for poor prognosis of SLE.Therefore, the study the pathogenesis of SLE-associated thrombocytopenia has been the focus of SLE treatment, Thrombopoietin (TPO) is the main cytokines that promotes the maturation, differentiation, and platelet release of bone marrow megakaryocytes and plays a physiological effect by binding to the specific receptor c-mpl on the target cell membrane.The role of anti-TPO antibody and anti-c-mpl antibody in the pathogenesis of SLE-associated thrombocytopenia was briefly summarized in this review.%血小板减少症是系统性红斑狼疮(systemic lupus erythematosus,SLE)的常见临床表现,是SLE预后不良的独立危险因素.研究SLE伴血小板减少的发病机制是SLE治疗领域的重点,血小板生成素(thrombopoietin,TPO)是促进骨髓巨核细胞成熟、分化、释放血小板的主要细胞因子,通过与靶细胞膜上特异性血小板生成素受体(c-mpl)结合发挥生理效应.本文对抗TPO抗体及抗c-mpl抗体在SLE伴血小板减少发病中的作用进行综述.